Daily, oral, preexposure prophylaxis (PrEP) is a recently introduced biomedical strategy to reduce the risk of human immunodeficiency virus (HIV) acquisition in HIV-negative adults. With adherence to daily doses of a pill containing 300 mg tenofovir disoproxil fumarate coformulated with 200 mg emtricitabine (Truvada), multiple clinical trials and open-label studies have demonstrated >90% reduction in sexual HIV acquisition and >70% reduction among persons who inject drugs (PWID). The Centers for Disease Control and Prevention (CDC) issued interim guidance for PrEP prescription in February 2011 [1] , the US Food and Drug Administration (FDA) approved a Truvada indication for PrEP in July 2012, and the CDC issued comprehensive clinical guidelines in May 2014 [2] . Both community and clinician education have occurred since 2011 to increase uptake for PrEP. The CDC estimates that 1.2 million persons in the United States have risk behaviors that constitute indications for PrEP use [3] . PrEP prescriptions have been steadily increasing but are still <10% of those estimated to have indications for PrEP use, with marked disparities by race/ethnicity, age, transmission risk group, and gender when compared to rates of new HIV infections [4] .
Our objective in this study was to investigate the characteristics and proportion of newly diagnosed HIV-infected individuals in South Carolina who, if they had been prescribed PrEP when visiting healthcare providers while HIV uninfected, could have been prevented from acquiring the disease.
METHODS
This population-based retrospective cohort study links HIV case surveillance data to 3 additional databases: the Department of Health and Environmental Control's (DHEC's) Bureau of Laboratory (BOL) System, South Carolina's Sexually Transmitted Disease Management Information System (STD*MIS), and the Revenue and Fiscal Affairs (RFA) inpatient, outpatient, and emergency department hospital discharge database. These databases contain medical encounters of all STD-related visits occurring in any of South Carolina's health departments' STD/family planning clinics, private physician practices, laboratories, or hospital settings from 1 January 2011 through 31 December 2016. Investigators searched the linked databases for clinician-diagnosed or laboratory-confirmed reportable STDs. This study was approved by the South Carolina DHEC, the University of South Carolina institutional review boards, and the RFA Data Oversight Committee.
Study Data

South Carolina-DHEC Enhanced HIV/AIDS Reporting System
HIV case reports and dates of first HIV diagnosis for the study were obtained from the South Carolina-DHEC enhanced HIV/ AIDS Reporting System (eHARS). South Carolina eHARS data quality ratings exceed the CDC minimum standards of reporting timeliness and completeness (95% of the cases are reported within 6 months of diagnosis and 98% complete reporting based on a comparison with other data sources [South Carolina-DHEC unpublished data, December 2015]). The eHARS data file had duplicate records removed. In addition, all licensed laboratories operating in South Carolina are mandated by law, since January 2004, to report all CD4+ T-cell counts (CD4) and HIV viral load test results to South Carolina-DHEC, and these laboratory results are recorded in eHARS.
For the analysis, we first selected records for individuals newly diagnosed with HIV infection from 1 January 2013 through 31 December 2016 who were aged ≥13 years and who were residents of South Carolina at the time of HIV diagnosis. To exclude persons with unrecognized, long-standing HIV infection (who would not have been prescribed PrEP at visits prior to their HIV diagnosis date in this dataset), we included only infected persons with CD4 T-cell counts ≥500 cells/ mm 3 .
Infected persons with incomplete HIV report dates (missing year) were also excluded from the analysis. In analyses with residence at diagnosis as a variable of interest, patients with unknown residence were excluded. The covariates captured from eHARS included the following: age at diagnosis (13- 
RFA Data
In accordance with South Carolina state law, the RFA has received healthcare data from emergency departments, hospital inpatient facilities, hospital ambulatory care facilities, and outpatient surgery facilities within South Carolina since 1996. These South Carolina healthcare facilities report greater than 98% of their data to the RFA within 1 year from date of collection (RFA, unpublished data, 2015). Each individual who has accessed healthcare services from these facilities is assigned a unique patient identifier number that has been validated internally by the RFA. Partial data are available from free health clinics, and no data are available from private physicians not affiliated with a healthcare system.
For the purposes of this analysis, we extracted the following healthcare data: International Classification of Diseases (ICD) 9th and 10th edition codes, admission dates at healthcare facilities, source of payment at last visit, location of the care facility, physician specialty code, and patient zip code.
Healthcare data for this report were supplied by 66 emergency departments, 64 inpatient facilities, and 156 ambulatory facilities or outpatient surgery facilities in South Carolina for visits that occurred from 1 January 2011 through 31 December 2016.
ICD codes from all healthcare visits made before the first positive HIV test date (see eHARS section above) were investigated for sexually transmitted infections (primary and secondary syphilis, gonorrhea, and chlamydia) occurring prior to HIV diagnosis.
South Carolina DHEC BOL System
The following variables were received from the South Carolina DHEC BOL: unique state identification number, gender, race/ ethnicity, county of patient's residence, birth date (month and year), date of test, type of test, program (DHEC program where tested), quantified result, and qualified result of test (negative, positive, unknown).
The following variables were received from STD*MIS: patient name, gender, race/ethnicity, county of patient's residence, social security number, birth date, STD diagnosed, and diagnosis date of STD. Two methods were used to define an STD: a clinician diagnosis or a laboratory-confirmed report for gonorrhea; primary, secondary, or early latent syphilis; or chlamydia that occurred at least 30 days before an HIV diagnosis. The 30-day cutoff in assessing STD acquisition was an attempt to minimize STDs that would only have been identified at the time of the initial HIV diagnosis and therefore would not have been an indication for prescription of PrEP because the individual was already infected. Investigators considered individuals free of STDs if there were no case reports recorded in the linked datasets during the study period.
A new case of syphilis was defined as a non-treponemal test with at least a 4-fold increase in titer compared to the titer from the most recent non-treponemal test or the first positive non-treponemal test with an associated positive treponemal test. A new case of gonorrhea/chlamydia was defined as either a laboratory-confirmed nucleic acid amplification test or a clinician diagnosis (eg, gram-negative intracellular diplococci or leukocytes on Gram stain smear).
Data Linkage
The eHARS and the RFA healthcare data files were linked using patient name, birth date, gender, race/ethnicity, social security number (if available), and county of residence. The date of the first positive HIV test recorded in eHARS was used to identify encounters from the RFA healthcare database that occurred before that date. Authorized persons trained in eHARS security guidelines and Health Insurance Portability and Accountability Act confidentiality procedures linked the data in a secured location. All identifiers (names, addresses, and social security numbers) were removed, and de-identified data were then provided to the investigators.
Data Analyses
We performed descriptive analyses on data from HIV-infected individuals who received a first positive HIV diagnosis beginning in 2013, 6 months after PrEP received FDA approval. We investigated factors potentially associated with missed opportunities to provide PrEP at healthcare visits prior to HIV diagnosis, including patient demographics (age, race/ethnicity, gender), behavioral risk (MSM, PWID, heterosexual, NIR/ NRR), provider specialty when encountered, hospital setting (inpatient, outpatient, and emergency department), diagnosis with a bacterial STD, frequency of visits prior to HIV diagnosis (1 visit, 2-5 visits, 6-10 visits, >10 visits), residence at the time of HIV diagnosis (rural/urban), and source of payment for visits (self-pay, none, private insurance, Medicaid, Medicare, other).
For visits prior to HIV diagnosis from 1 January 2011 to 31 December 2016, we categorized the specialty physician who encountered the patient at each visit (primary care, emergency medicine, other) and ranked the top 10 ICD-9 and ICD-10 coded reasons for visits. Healthcare visits for STDs were identified from 2 sources. First, ICD-9 and ICD-10 coders from FRA data were used to identify STD-related visits. Second, South Carolina DHEC BOL data were linked to FRA data and used to identify STD-related visits.
RESULTS
Of the 885 newly diagnosed persons in this analysis, 586 (66%) had visited a healthcare facility prior to their HIV diagnosis. Assessed patients had a mean of 6.9 healthcare visits prior to their date of HIV diagnosis (median, 4.0 visits); this represents several missed opportunities for PrEP evaluation and prescription. Of 4029 visits, most visits (84%) were to emergency departments, whereas few were conducted in outpatient (7%) or inpatient (6%) facilities. Most visits were conducted by emergency medicine-trained clinicians (61%), and 10% of visits were conducted by primary care clinicians (family practice or internal medicine). A majority of visits were by persons who were uninsured or self-pay (42%), while public insurance was listed for 36% and commercial insurance was listed for 18% (Table 1) . Few Hispanic/Latino persons were identified (Table 2) .
Bivariate analysis found that persons with missed visit opportunities for PrEP provision were more likely to be female than male (P < .0001), black than white (P < .0001), and aged <30 years compared to older persons (P < .0003; Table 2 ). In multivariable analysis, these 3 factors remain statistically significant predictors of having prior healthcare visits ( Table 3) .
The 10 most frequent diagnoses recorded at these visits (n = 10 350 diagnoses) represent a range of conditions, including tobacco use disorder/nicotine dependence (8.6%), hypertension (8.3%), long-term drug therapy (4.0%), diabetes mellitus (3.2%), headache (2.3%), major depressive episode (1.6%), urinary tract infection (1.5%), accident (1.4%), anxiety state (1.4%), and asthma (1.3%).
Among persons with 1 or more healthcare visits prior to their HIV diagnosis, 24.7% had a diagnosis of gonorrhea or syphilis at at least 1 healthcare visit, and 28.5% had a diagnosis of gonorrhea, syphilis, or chlamydia (Table 3) . among persons with an STD diagnosis [10] . Missed opportunities for HIV testing reduce the ability to start antiretroviral treatment and achieve viral suppression as early as possible for the health benefit to the person with HIV infection and to reduce transmission to others. However, missed opportunities for HIV testing also represent missed opportunities to evaluate uninfected patients for their risk of HIV acquisition and provision of PrEP for its prevention. One recent study assessed missed opportunities for providing PrEP at antenatal visits to prevent HIV acquisition during pregnancy by women in a high-prevalence setting [11] . This is the first evaluation focused on missed opportunities to provide PrEP to a broad population of persons, from multiple transmission risk groups, at healthcare visits before they were first diagnosed with HIV infection. We documented that among persons diagnosed with HIV infection who had an initial CD4 count ≥500 cells/mm 3 suggestive of more recent infection, 2/3 had prior visits to a healthcare facility, which is similar to findings from another study [5] . These visits occurred after the date of CDC issuance of the first interim guidance for prescription of daily Truvada for PrEP and so are likely to represent missed opportunities for its use to prevent HIV acquisition. Black MSM, black women, and young MSM have the highest risk of HIV infection. The finding that these groups were more likely to have had healthcare visits prior to their HIV diagnosis suggests an important impact of missed opportunities to provide them with PrEP. A similar pattern is seen among racial/ethnic minority young persons with other diseases [12] . Similarly, the finding that ¼ had an STD diagnosis at a prior healthcare visit suggests that clinicians may not be responding to the fact that gonorrhea and syphilis are strongly suggestive of risk for HIV acquisition in both MSM [13, 14] and heterosexually active women [15] . The finding that Hispanic/Latino persons were significantly less likely to have had a prior healthcare visit is concerning given that rates of new infections are rising among young Hispanic/Latino MSM.
DISCUSSION
Several previous analyses have assessed missed opportunities for HIV testing to diagnose HIV infection [5-9], including
Emergency medicine providers conducted the majority of healthcare visits. While infectious disease and primary care clinicians have been the focus of initial provider education and training about PrEP, early assessments of the specialty of PrEP prescribers in pharmacy databases have found substantial numbers of emergency medicine providers [16] . Emergency medicine providers have expressed interest in being trained to initiate PrEP when indicated and provide linkage to continuity care for follow-up [17, 18] .
There are limitations to this retrospective surveillance cohort analysis approach. We used CD4 count at diagnosis ≥500 cells/ mm 3 as a proxy measure to exclude long-standing HIV infection (ie, late diagnosis) but recognize that this proxy does not discriminate precisely. HIV testing history is not available for visits prior to the date of the first positive HIV test result. Prescription data were not available for this analysis, there are no ICD codes specific to PrEP, and the records contain no documentation of whether PrEP was offered or refused. However, PrEP use, as determined by prescriptions in a national pharmacy database [19] , showed only 72 prevalent PrEP users in 2012, with a slow increase to 474 in 2016. This strongly suggests that nearly all of the persons identified in this analysis were not provided PrEP at healthcare visits prior to the date of their HIV diagnosis.
CONCLUSIONS
Although PrEP uptake has been increasing nationwide, its delivery in the southern states where the majority of new HIV diagnoses are now for African American men and women and young Hispanic/Latino men has been disturbingly low [4] . To urgently address these geographic and demographic inequities, it is necessary to increase healthcare utilization among black men and women and among Hispanic/Latino men, reduce the number of missed opportunities for HIV testing at all healthcare visits, and identify indications for PrEP use in HIV-negative persons, especially those with diagnosed bacterial STDs, so that PrEP for HIV prevention can be provided.
Notes
